Study details
Enrolling now
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
Icahn School of Medicine at Mount Sinai
NCT IDNCT04353778ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
55
Study length
about 5.5 years
Ages
18+
Locations
1 site in NY
What this study is about
Researchers are testing whether a treatment, non-invasive vagal nerve stimulation, or pyridostigmine can help with gastrointestinal problems and inflammation linked to vagus nerve dysfunction in people living with HIV. The trial will explore how the vagus nerve affects inflammation in the gut of people with HIV.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebos
- 2.Take Pyridostigmine
- 3.Undergo non-invasive vagal nerve stimulation
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
pyridostigmine
Endpoints
Primary: IL6 measurement [Time Frame: 5 years]
Procedures
therapy
Body systems
Immune, Infectious